News Article

SphynKx developing modulators of endogenous S1P to treat fibrosis
Date: Nov 11, 2013
Author: Emily Cukier-Meisner
Source: Biocentury.com ( click here to go to the source)

Featured firm in this article: SphynKx Therapeutics LLC of Charlottesville, VA



SphynKx Therapeutics LLC is developing a portfolio of sphingosine kinase inhibitors that can up- or down-regulate blood levels of sphingosine 1-phosphate to treat fibrosis in different organs.

The company's lead program focuses on preventing fibrosis in chronic kidney disease by increasing circulating sphingosine 1-phosphate (S1P). A less advanced program seeks to treat idiopathic pulmonary fibrosis (IPF) by lowering S1P.